FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 9, 2012, Pages 1341-1352

  Taylor, Patricia A ^a   Kelly, Ryan M ^a   Bade, Nick D ^a   Smith, Michelle J ^a   Stefanski, Heather E ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Animal model; Bone marrow transplantation; Thymopoiesis

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; FINGOLIMOD;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL HOMING; CELL LINEAGE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; LYMPHOCYTE DIFFERENTIATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRE T LYMPHOCYTE; T LYMPHOCYTE; THYMOCYTE; THYMUS;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CD40 LIGAND; CELL MOVEMENT; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; MICE; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES; THYMOCYTES; THYMUS GLAND; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84865159873     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.06.007     Document Type: Article

References (34)

1. Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 2004, 45:991-997.
2. Brinkmann V., Lynch K.R. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002, 14:569-575.
3. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005, 108:308-319.
4. Hla T., Lee M.J., Ancellin N., et al. Lysophospholipids-receptor revelations. Science 2001, 294:1875-1878.
5. Pyne S., Pyne N. Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther 2000, 88:115-131.
6. Yopp A.C., Ledgerwood L.G., Ochando J.C., et al. Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. Clin Transplant 2006, 20:788-795.
7. Chen S., Bacon K.B., Garcia G., et al. FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. Transplant Proc 2001, 33:3057-3063.
8. Gossens K., Naus S., Corbel S.Y., et al. Thymic progenitor homing and lymphocyte homeostasis are linked via S1P-controlled expression of thymic P-selectin/CCL25. J Exp Med 2009, 206:761-778.
9. Matloubian M., Lo C.G., Cinamon G., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
10. + progenitor cells. Blood 2004, 103:4478-4486.
11. Brinkmann V., Pinschewer D.D., Feng L., et al. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001, 72:764-769.
12. Warnke C., Stuve O., Hartung H.P., et al. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2011, 7:519-527.
13. Hashimoto D., Asakura S., Matsuoka K., et al. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Eur J Immunol 2007, 37:271-281.
14. Kataoka H., Ohtsuki M., Shimano K., et al. Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist, II: effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice. Transplant Proc 2005, 37:107-109.
15. Kim Y.M., Sachs T., Asavaroengchai W., et al. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clinical Invest 2003, 111:659-669.
16. Taylor P.A., Ehrhardt M.J., Lees C.J., et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007, 110:3480-3488.
17. Schmitt T.M., Zuniga-Pflucker J.C. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002, 17:749-756.
18. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 1997, 158:29-39.
19. Yagi H., Kamba R., Chiba K., et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000, 30:1435-1444.
20. Seitz G., Boehmler A.M., Kanz L., et al. The role of sphingosine 1-phosphate receptors in the trafficking of hematopoietic progenitor cells. Ann NY Acad Sci 2005, 1044:84-89.
21. Walter D.H., Rochwalsky U., Reinhold J., et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 2007, 27:275-282.
22. Durham M.M., Bingaman A.W., Adams A.B., et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000, 165:1-4.
23. Larsen C.P., Elwood E.T., Alexander D.Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
24. Parker D.C., Greiner D.L., Phillips N.E., et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995, 92:9560-9564.
25. Seung E., Iwakoshi N., Woda B.A., et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000, 95:2175-2182.
26. Taylor P.A., Lees C.J., Waldmann H., et al. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001, 98:467-474.
27. Wekerle T., Kurtz J., Ito H., et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000, 6:464-469.
28. Blazar B.R., Taylor P.A., Sehgal S.N., et al. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 1994, 83:600-609.
29. Taylor P.A., Lees C.J., Wilson J.M., et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002, 100:3400-3407.
30. Taylor P.A., Panoskaltsis-Mortari A., Freeman G.J., et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 2005, 105:3372-3380.
31. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 104:3804-3812.
32. Hidalgo A., Sanz-Rodriguez F., Rodriguez-Fernandez J.L., et al. Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells. Exp Hematol 2001, 29:345-355.
33. Lataillade J.J., Clay D., Dupuy C., et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000, 95:756-768.
34. Peled A., Kollet O., Ponomaryov T., et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000, 95:3289-3296.